CA1186221A - Compose et methode pour la detection du cancer faisant appel a des fragments d'anticorps marques au technetium - Google Patents

Compose et methode pour la detection du cancer faisant appel a des fragments d'anticorps marques au technetium

Info

Publication number: CA1186221A
Authority: CA; Canada
Prior art keywords: antibody; antibody fragment; hcg; technetium; radiolabeled
Prior art date: 1981-06-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000404269A

Other languages

English (en)

Inventor

David R. Crockford

Buck A. Rhodes

Scott W. Burchiel

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Summa Medical Corp

University Patents Inc

Original Assignee

Summa Medical Corp

University Patents Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-06-02

Filing date

1982-06-02

Publication date

1985-04-30

1981-06-02 Priority claimed from US06/269,404 external-priority patent/US4478815A/en

1982-06-02 Application filed by Summa Medical Corp, University Patents Inc filed Critical Summa Medical Corp

1983-10-26 Priority to CA000439805A priority Critical patent/CA1186620A/fr

1985-04-30 Application granted granted Critical

1985-04-30 Publication of CA1186221A publication Critical patent/CA1186221A/fr

Status Expired legal-status Critical Current

Links

206010028980 Neoplasm Diseases 0.000 title claims abstract description 51
239000000203 mixture Substances 0.000 title claims abstract description 26
201000011510 cancer Diseases 0.000 title claims abstract description 19
102000008394 Immunoglobulin Fragments Human genes 0.000 title claims description 57
108010021625 Immunoglobulin Fragments Proteins 0.000 title claims description 57
229910052713 technetium Inorganic materials 0.000 title claims description 14
GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 title claims description 14
238000000034 method Methods 0.000 title abstract description 35
229940084986 human chorionic gonadotropin Drugs 0.000 claims abstract description 36
239000000427 antigen Substances 0.000 claims abstract description 34
102000036639 antigens Human genes 0.000 claims abstract description 34
108091007433 antigens Proteins 0.000 claims abstract description 34
239000000463 material Substances 0.000 claims abstract description 9
239000000243 solution Substances 0.000 claims description 30
GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 claims description 21
229940056501 technetium 99m Drugs 0.000 claims description 21
102000004169 proteins and genes Human genes 0.000 claims description 18
108090000623 proteins and genes Proteins 0.000 claims description 18
239000003638 chemical reducing agent Substances 0.000 claims description 9
150000002500 ions Chemical class 0.000 claims description 4
230000027455 binding Effects 0.000 claims description 3
239000007864 aqueous solution Substances 0.000 claims description 2
238000002156 mixing Methods 0.000 claims description 2
IJURHEULXOSBQA-UHFFFAOYSA-N technetium(4+) Chemical compound [Tc+4] IJURHEULXOSBQA-UHFFFAOYSA-N 0.000 claims description 2
230000009257 reactivity Effects 0.000 claims 3
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims 1
238000009007 Diagnostic Kit Methods 0.000 claims 1
239000003456 ion exchange resin Substances 0.000 claims 1
229920003303 ion-exchange polymer Polymers 0.000 claims 1
102000011022 Chorionic Gonadotropin Human genes 0.000 abstract description 38
108010062540 Chorionic Gonadotropin Proteins 0.000 abstract description 38
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 abstract description 14
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 abstract description 14
108010022366 Carcinoembryonic Antigen Proteins 0.000 abstract description 10
238000001514 detection method Methods 0.000 abstract description 6
102000013529 alpha-Fetoproteins Human genes 0.000 abstract description 3
108010026331 alpha-Fetoproteins Proteins 0.000 abstract description 3
201000001441 melanoma Diseases 0.000 abstract description 3
230000002285 radioactive effect Effects 0.000 abstract description 2
239000012217 radiopharmaceutical Substances 0.000 abstract description 2
229940121896 radiopharmaceutical Drugs 0.000 abstract description 2
230000002799 radiopharmaceutical effect Effects 0.000 abstract description 2
102000012406 Carcinoembryonic Antigen Human genes 0.000 abstract 2
230000004807 localization Effects 0.000 abstract 2
108010001267 Protein Subunits Proteins 0.000 abstract 1
206010039491 Sarcoma Diseases 0.000 abstract 1
238000009825 accumulation Methods 0.000 abstract 1
238000012544 monitoring process Methods 0.000 abstract 1
239000012634 fragment Substances 0.000 description 28
241001465754 Metazoa Species 0.000 description 18
241000894007 species Species 0.000 description 17
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
210000004027 cell Anatomy 0.000 description 10
239000000872 buffer Substances 0.000 description 9
102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 8
229920005654 Sephadex Polymers 0.000 description 8
239000012507 Sephadex™ Substances 0.000 description 8
229920002684 Sepharose Polymers 0.000 description 8
241000283973 Oryctolagus cuniculus Species 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
241001494479 Pecora Species 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
238000002372 labelling Methods 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
239000011734 sodium Substances 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
230000000694 effects Effects 0.000 description 5
238000003384 imaging method Methods 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 5
238000012360 testing method Methods 0.000 description 5
102000008100 Human Serum Albumin Human genes 0.000 description 4
108091006905 Human Serum Albumin Proteins 0.000 description 4
229910008066 SnC12 Inorganic materials 0.000 description 4
239000011324 bead Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000011534 incubation Methods 0.000 description 4
229910052740 iodine Inorganic materials 0.000 description 4
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 3
229940015047 chorionic gonadotropin Drugs 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000010253 intravenous injection Methods 0.000 description 3
239000011630 iodine Substances 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
238000000163 radioactive labelling Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
102000003505 Myosin Human genes 0.000 description 2
108060008487 Myosin Proteins 0.000 description 2
241000609499 Palicourea Species 0.000 description 2
108090000526 Papain Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
102000011923 Thyrotropin Human genes 0.000 description 2
108010061174 Thyrotropin Proteins 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
239000003957 anion exchange resin Substances 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
239000008366 buffered solution Substances 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
229960005156 digoxin Drugs 0.000 description 2
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
229940028334 follicle stimulating hormone Drugs 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
238000001114 immunoprecipitation Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000006192 iodination reaction Methods 0.000 description 2
239000003446 ligand Substances 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
229940055729 papain Drugs 0.000 description 2
235000019834 papain Nutrition 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000006722 reduction reaction Methods 0.000 description 2
238000007086 side reaction Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
229940095064 tartrate Drugs 0.000 description 2
IUTCEZPPWBHGIX-UHFFFAOYSA-N tin(2+) Chemical compound [Sn+2] IUTCEZPPWBHGIX-UHFFFAOYSA-N 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
238000005406 washing Methods 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
101710125089 Bindin Proteins 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
241000283707 Capra Species 0.000 description 1
208000006332 Choriocarcinoma Diseases 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
102000003864 Human Follicle Stimulating Hormone Human genes 0.000 description 1
108010082302 Human Follicle Stimulating Hormone Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
LKDRXBCSQODPBY-NSHGFSBMSA-N L-fructose Chemical compound OCC1(O)OC[C@H](O)[C@H](O)[C@H]1O LKDRXBCSQODPBY-NSHGFSBMSA-N 0.000 description 1
102000009151 Luteinizing Hormone Human genes 0.000 description 1
108010073521 Luteinizing Hormone Proteins 0.000 description 1
OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
241000282520 Papio Species 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000003513 alkali Substances 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000036765 blood level Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000009920 chelation Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
-1 cyanogen halide Chemical class 0.000 description 1
229960002433 cysteine Drugs 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
238000010586 diagram Methods 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
GOMCKELMLXHYHH-UHFFFAOYSA-L dipotassium;phthalate Chemical compound [K+].[K+].[O-]C(=O)C1=CC=CC=C1C([O-])=O GOMCKELMLXHYHH-UHFFFAOYSA-L 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000012149 elution buffer Substances 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
229940114119 gentisate Drugs 0.000 description 1
239000011521 glass Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000026045 iodination Effects 0.000 description 1
XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 1
PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229940040129 luteinizing hormone Drugs 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
229950006780 n-acetylglucosamine Drugs 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000009206 nuclear medicine Methods 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
229940043515 other immunoglobulins in atc Drugs 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
150000004053 quinones Chemical class 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000004513 sizing Methods 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229940033078 sodium pertechnetate tc 99m Drugs 0.000 description 1
239000001476 sodium potassium tartrate Substances 0.000 description 1
235000011006 sodium potassium tartrate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
229940043517 specific immunoglobulins Drugs 0.000 description 1
LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
229910052723 transition metal Inorganic materials 0.000 description 1
150000003624 transition metals Chemical class 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
230000001573 trophoblastic effect Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1

Landscapes

Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CA000404269A 1981-06-02 1982-06-02 Compose et methode pour la detection du cancer faisant appel a des fragments d'anticorps marques au technetium Expired CA1186221A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000439805A CA1186620A (fr)	1981-06-02	1983-10-26	Compose et methode pour detecter le cancer a l'aide de fragments d'anticorps marques au technetium

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US269,404		1981-06-02
US06/269,404 US4478815A (en)	1979-10-29	1981-06-02	Composition and method for detecting cancer with technetium labeled antibody fragments

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000439805A Division CA1186620A (fr)	1981-06-02	1983-10-26	Compose et methode pour detecter le cancer a l'aide de fragments d'anticorps marques au technetium

Publications (1)

Publication Number	Publication Date
CA1186221A true CA1186221A (fr)	1985-04-30

Family

ID=23027099

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000404269A Expired CA1186221A (fr)	1981-06-02	1982-06-02	Compose et methode pour la detection du cancer faisant appel a des fragments d'anticorps marques au technetium

Country Status (1)

Country	Link
CA (1)	CA1186221A (fr)

1982
- 1982-06-02 CA CA000404269A patent/CA1186221A/fr not_active Expired

Legal Events

Date	Code	Title	Description
2002-05-01	MKEC	Expiry (correction)
2002-06-02	MKEX	Expiry

Publication	Publication Date	Title
US4478815A (en)	1984-10-23	Composition and method for detecting cancer with technetium labeled antibody fragments
EP0005638B1 (fr)	1983-09-21	Composition comprenant un anticorps marqué au Tc-99m et une trousse de diagnostic pour la préparation de la composition
JP3051339B2 (ja)	2000-06-12	治療的抗白血球結合体及び哺乳動物用非経口的注射剤
US4472371A (en)	1984-09-18	Radiolabeled antibody to anti-tumor associated antigen and process
Mather et al.	1990	Reduction-mediated technetium-99m labeling of monoclonal antibodies
US4424200A (en)	1984-01-03	Method for radiolabeling proteins with technetium-99m
US4421735A (en)	1983-12-20	Radiolabeled diagnostic compositions and method for making the same
US4444744A (en)	1984-04-24	Tumor localization and therapy with labeled antibodies to cell surface antigens
US5990286A (en)	1999-11-23	Antibodies with reduced net positive charge
EP0354923B1 (fr)	1994-06-29	Procede de marquage d'anticorps a l'aide d'un ion metallique
Khaw et al.	1984	Sequential imaging of indium-111-labeled monoclonal antibody in human mammary tumors hosted in nude mice
WO1991014453A1 (fr)	1991-10-03	Methode amelioree de radiomarquage direct d'anticorps pour l'imagerie diagnostique et la therapie
JPH03157338A (ja)	1991-07-05	ヒト腫瘍造影用注射組成物
US5439665A (en)	1995-08-08	Detection and treatment of infectious and inflammatory lesions
USRE32417E (en)	1987-05-12	Radiolabeled antibody to anti-tumor associated antigen and process
Carney et al.	1989	Dual isotope study of iodine-125 and indium-111-labeled antibody in athymic mice
CA1339415C (fr)	1997-09-02	Detection et traitement des infections au moyen d'immunoconjugues
CA1186221A (fr)	1985-04-30	Compose et methode pour la detection du cancer faisant appel a des fragments d'anticorps marques au technetium
CA1186620A (fr)	1985-05-07	Compose et methode pour detecter le cancer a l'aide de fragments d'anticorps marques au technetium
CA1338982C (fr)	1997-03-11	Detection de lesions infectieuses et inflammatoires a l'aide de conjugues anticorps anti-leucocytes
Hirshaut et al.	1987	Human Sarcoma-associated Murine Monoclonal Antibody Labeled With Indium-111, Gallium-67, and lodine-1251
Mather et al.	0	Reduction-Mediated Technetium-99m
Mather	1988	Radioiodinated monoclonal antibodies
Varvarigou	1998	Radiolabelling of antibodies with technetium-99m and their clinical evaluation
JPH05501107A (ja)	1993-03-04	画像用放射標識抗体